Sun Pharma Advanced Research Company Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase-1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors.

Antibody?drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells.

SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumours. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the antimitotic payload after internalization and cleavage.

The released payload inhibits cell division and, thereby contributes to the shrinkage of tumours. SPARC had licensed anti-MUC1 antibody from Biomodifying a startup from the University of Tel Aviv.

Anil Raghavan, CEO of SPARC, said: SBO-154, our first ADC is ready to advance in phase-1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally.

Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery.

The scrip had declined 2.63% to end at Rs 148 on the BSE on Friday.

Powered by Capital Market - Live News

Sun Pharma Advanced Research Company announced submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase 1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors.

?SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally.? said Anil Raghavan, CEO of SPARC.

SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumors. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the antimitotic payload after internalization and cleavage. The released payload inhibits cell division and, thereby contributes to the shrinkage of tumors. SPARC had licensed anti-MUC1 antibody from Biomodifying a startup from the University of Tel Aviv.

Powered by Capital Market - Live News

Kalpataru Projects International Ltd, Inox Wind Ltd, Data Patterns (India) Ltd, Triveni Turbine Ltd are among the other stocks to see a surge in volumes on NSE today, 07 March 2025.

Sun Pharma Advanced Research Company Ltd saw volume of 210.38 lakh shares by 14:14 IST on NSE, a 10.63 fold spurt over two-week average daily volume of 19.80 lakh shares. The stock increased 9.66% to Rs.138.23. Volumes stood at 12.07 lakh shares in the last session.

Kalpataru Projects International Ltd registered volume of 59.12 lakh shares by 14:14 IST on NSE, a 7.78 fold spurt over two-week average daily volume of 7.60 lakh shares. The stock rose 3.48% to Rs.948.95. Volumes stood at 26 lakh shares in the last session.

Inox Wind Ltd recorded volume of 532.12 lakh shares by 14:14 IST on NSE, a 7.47 times surge over two-week average daily volume of 71.21 lakh shares. The stock gained 11.36% to Rs.170.60. Volumes stood at 45.97 lakh shares in the last session.

Data Patterns (India) Ltd witnessed volume of 82.39 lakh shares by 14:14 IST on NSE, a 7.36 times surge over two-week average daily volume of 11.19 lakh shares. The stock increased 11.39% to Rs.1,583.00. Volumes stood at 5.2 lakh shares in the last session.

Triveni Turbine Ltd clocked volume of 129.41 lakh shares by 14:14 IST on NSE, a 5.98 times surge over two-week average daily volume of 21.65 lakh shares. The stock gained 9.89% to Rs.588.75. Volumes stood at 85.59 lakh shares in the last session.

Powered by Capital Market - Live News

Sun Pharma Advanced Research Company announced submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase 1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors.

?SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally.? said Anil Raghavan, CEO of SPARC.

SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumors. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the antimitotic payload after internalization and cleavage. The released payload inhibits cell division and, thereby contributes to the shrinkage of tumors. SPARC had licensed anti-MUC1 antibody from Biomodifying a startup from the University of Tel Aviv.

Powered by Capital Market - Live News

Kalpataru Projects International Ltd, Inox Wind Ltd, Data Patterns (India) Ltd, Triveni Turbine Ltd are among the other stocks to see a surge in volumes on NSE today, 07 March 2025.

Sun Pharma Advanced Research Company Ltd saw volume of 210.38 lakh shares by 14:14 IST on NSE, a 10.63 fold spurt over two-week average daily volume of 19.80 lakh shares. The stock increased 9.66% to Rs.138.23. Volumes stood at 12.07 lakh shares in the last session.

Kalpataru Projects International Ltd registered volume of 59.12 lakh shares by 14:14 IST on NSE, a 7.78 fold spurt over two-week average daily volume of 7.60 lakh shares. The stock rose 3.48% to Rs.948.95. Volumes stood at 26 lakh shares in the last session.

Inox Wind Ltd recorded volume of 532.12 lakh shares by 14:14 IST on NSE, a 7.47 times surge over two-week average daily volume of 71.21 lakh shares. The stock gained 11.36% to Rs.170.60. Volumes stood at 45.97 lakh shares in the last session.

Data Patterns (India) Ltd witnessed volume of 82.39 lakh shares by 14:14 IST on NSE, a 7.36 times surge over two-week average daily volume of 11.19 lakh shares. The stock increased 11.39% to Rs.1,583.00. Volumes stood at 5.2 lakh shares in the last session.

Triveni Turbine Ltd clocked volume of 129.41 lakh shares by 14:14 IST on NSE, a 5.98 times surge over two-week average daily volume of 21.65 lakh shares. The stock gained 9.89% to Rs.588.75. Volumes stood at 85.59 lakh shares in the last session.

Powered by Capital Market - Live News

Net Loss of Sun Pharma Advanced Research Company reported to Rs 79.51 crore in the quarter ended December 2024 as against net loss of Rs 99.65 crore during the previous quarter ended December 2023. Sales rose 7.58% to Rs 14.91 crore in the quarter ended December 2024 as against Rs 13.86 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News

The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase-1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors.

Antibody?drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells.

SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumours. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the antimitotic payload after internalization and cleavage.

The released payload inhibits cell division and, thereby contributes to the shrinkage of tumours. SPARC had licensed anti-MUC1 antibody from Biomodifying a startup from the University of Tel Aviv.

Anil Raghavan, CEO of SPARC, said: SBO-154, our first ADC is ready to advance in phase-1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally.

Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery.

The scrip had declined 2.63% to end at Rs 148 on the BSE on Friday.

Powered by Capital Market - Live News

Sun Pharma Advanced Research Company announced submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase 1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors.

?SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally.? said Anil Raghavan, CEO of SPARC.

SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumors. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the antimitotic payload after internalization and cleavage. The released payload inhibits cell division and, thereby contributes to the shrinkage of tumors. SPARC had licensed anti-MUC1 antibody from Biomodifying a startup from the University of Tel Aviv.

Powered by Capital Market - Live News

Kalpataru Projects International Ltd, Inox Wind Ltd, Data Patterns (India) Ltd, Triveni Turbine Ltd are among the other stocks to see a surge in volumes on NSE today, 07 March 2025.

Sun Pharma Advanced Research Company Ltd saw volume of 210.38 lakh shares by 14:14 IST on NSE, a 10.63 fold spurt over two-week average daily volume of 19.80 lakh shares. The stock increased 9.66% to Rs.138.23. Volumes stood at 12.07 lakh shares in the last session.

Kalpataru Projects International Ltd registered volume of 59.12 lakh shares by 14:14 IST on NSE, a 7.78 fold spurt over two-week average daily volume of 7.60 lakh shares. The stock rose 3.48% to Rs.948.95. Volumes stood at 26 lakh shares in the last session.

Inox Wind Ltd recorded volume of 532.12 lakh shares by 14:14 IST on NSE, a 7.47 times surge over two-week average daily volume of 71.21 lakh shares. The stock gained 11.36% to Rs.170.60. Volumes stood at 45.97 lakh shares in the last session.

Data Patterns (India) Ltd witnessed volume of 82.39 lakh shares by 14:14 IST on NSE, a 7.36 times surge over two-week average daily volume of 11.19 lakh shares. The stock increased 11.39% to Rs.1,583.00. Volumes stood at 5.2 lakh shares in the last session.

Triveni Turbine Ltd clocked volume of 129.41 lakh shares by 14:14 IST on NSE, a 5.98 times surge over two-week average daily volume of 21.65 lakh shares. The stock gained 9.89% to Rs.588.75. Volumes stood at 85.59 lakh shares in the last session.

Powered by Capital Market - Live News

Sun Pharma Advanced Research Company announced submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA). The IND application supports the next phase of development of SBO-154 which has completed the required IND-enabling preclinical studies with favorable results. A global phase 1 dose-escalation and expansion study has been planned to evaluate SBO-154 in treatment of solid tumors.

?SBO-154, our first ADC is ready to advance in phase 1 with this IND submission, and this is an important milestone for SPARC as we hope to improve lives of cancer patients globally.? said Anil Raghavan, CEO of SPARC.

SBO-154 is a novel humanized MUC1-SEA-targeted ADC developed by SPARC for the treatment of advanced solid tumors. SBO-154 specifically binds with high affinity to the SEA domain of MUC1, and functions by the release of the antimitotic payload after internalization and cleavage. The released payload inhibits cell division and, thereby contributes to the shrinkage of tumors. SPARC had licensed anti-MUC1 antibody from Biomodifying a startup from the University of Tel Aviv.

Powered by Capital Market - Live News

Kalpataru Projects International Ltd, Inox Wind Ltd, Data Patterns (India) Ltd, Triveni Turbine Ltd are among the other stocks to see a surge in volumes on NSE today, 07 March 2025.

Sun Pharma Advanced Research Company Ltd saw volume of 210.38 lakh shares by 14:14 IST on NSE, a 10.63 fold spurt over two-week average daily volume of 19.80 lakh shares. The stock increased 9.66% to Rs.138.23. Volumes stood at 12.07 lakh shares in the last session.

Kalpataru Projects International Ltd registered volume of 59.12 lakh shares by 14:14 IST on NSE, a 7.78 fold spurt over two-week average daily volume of 7.60 lakh shares. The stock rose 3.48% to Rs.948.95. Volumes stood at 26 lakh shares in the last session.

Inox Wind Ltd recorded volume of 532.12 lakh shares by 14:14 IST on NSE, a 7.47 times surge over two-week average daily volume of 71.21 lakh shares. The stock gained 11.36% to Rs.170.60. Volumes stood at 45.97 lakh shares in the last session.

Data Patterns (India) Ltd witnessed volume of 82.39 lakh shares by 14:14 IST on NSE, a 7.36 times surge over two-week average daily volume of 11.19 lakh shares. The stock increased 11.39% to Rs.1,583.00. Volumes stood at 5.2 lakh shares in the last session.

Triveni Turbine Ltd clocked volume of 129.41 lakh shares by 14:14 IST on NSE, a 5.98 times surge over two-week average daily volume of 21.65 lakh shares. The stock gained 9.89% to Rs.588.75. Volumes stood at 85.59 lakh shares in the last session.

Powered by Capital Market - Live News

Net Loss of Sun Pharma Advanced Research Company reported to Rs 79.51 crore in the quarter ended December 2024 as against net loss of Rs 99.65 crore during the previous quarter ended December 2023. Sales rose 7.58% to Rs 14.91 crore in the quarter ended December 2024 as against Rs 13.86 crore during the previous quarter ended December 2023.

Powered by Capital Market - Live News